| Title |
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype
|
|---|---|
| Published in |
Clinical Pharmacology & Therapeutics, March 2014
|
| DOI | 10.1038/clpt.2014.54 |
| Pubmed ID | |
| Authors |
J P Clancy, S G Johnson, S W Yee, E M McDonagh, K E Caudle, T E Klein, M Cannavo, K M Giacomini |
| Abstract |
Cystic fibrosis (CF) is a life-shortening disease arising as a consequence of mutations within the CFTR gene. Novel therapeutics for CF are emerging that target CF transmembrane conductance regulator protein (CFTR) defects resulting from specific CFTR variants. Ivacaftor is a drug that potentiates CFTR gating function and is specifically indicated for CF patients with a particular CFTR variant, G551D-CFTR (rs75527207). Here, we provide therapeutic recommendations for ivacaftor based on preemptive CFTR genotype results. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 3 | 50% |
| Members of the public | 2 | 33% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | <1% |
| India | 1 | <1% |
| Canada | 1 | <1% |
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 99 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 16% |
| Student > Bachelor | 12 | 12% |
| Student > Master | 12 | 12% |
| Student > Ph. D. Student | 12 | 12% |
| Student > Doctoral Student | 8 | 8% |
| Other | 17 | 16% |
| Unknown | 26 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 13% |
| Biochemistry, Genetics and Molecular Biology | 11 | 11% |
| Agricultural and Biological Sciences | 8 | 8% |
| Economics, Econometrics and Finance | 2 | 2% |
| Other | 5 | 5% |
| Unknown | 32 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2018.
All research outputs
#3,362,903
of 23,818,521 outputs
Outputs from Clinical Pharmacology & Therapeutics
#650
of 4,275 outputs
Outputs of similar age
#33,905
of 222,741 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#9
of 38 outputs
Altmetric has tracked 23,818,521 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,275 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 222,741 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.